Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Denne studien vil evaluere effektiviteten til NTX-001, et kirurgisk nervereparasjonsprodukt, når det brukes hos personer med nerveskader i øvre ekstremiteter av sensoriske eller blandede motoriske nerver.

2. oktober 2026 oppdatert av: Neuraptive Therapeutics Inc.

En fase 3, multisenter, randomisert, blindet, kontrollert studie som evaluerer sikkerheten og effektiviteten til NTX-001 sammenlignet med standardbehandling (nevrorrafi) ved behandling av øvre ekstremitetstransected nerver som krever kirurgisk reparasjon.

NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 18 and 80.

Studieoversikt

Detaljert beskrivelse

NTX-001 has been developed as a surgical product to be used in conjunction with standard suture neurorrhaphy of a severed nerve. Use of NTX-001 is intended to safely accelerate the often slow and diminished return of function in repaired nerves. It often takes months and/or years to determine if function will be restored. By that point, restoration is often incomplete and can result in lifelong motor and/or sensory deficits. By reconnecting (PEG-fusion) a substantial number of axons within a severed nerve, the degeneration-regeneration cycle and subsequent atrophy may be reduced or even prevented for those axons and their targets, respectively. NTX-001 (PEG-fusion) has the potential to avoid the consequences of protracted denervation of distal target tissues by eliminating the period of total denervation thus reducing the time to stable recovery and providing greater innervation to affected tissues.

Studietype

Intervensjonell

Registrering (Antatt)

98

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • California
      • Los Angeles, California, Forente stater, 90048
        • Har ikke rekruttert ennå
        • Cedars Sinai Medical Center
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Meghan C McCullough, MD
      • San Francisco, California, Forente stater, 94158
        • Har ikke rekruttert ennå
        • UCSF Health
        • Ta kontakt med:
        • Ta kontakt med:
    • Florida
      • Orlando, Florida, Forente stater, 32806
      • Orlando, Florida, Forente stater, 32804
        • Rekruttering
        • Rothman Orthopedics - Advent Health
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amir Reza Kachooei, MD PhD
    • Georgia
      • Atlanta, Georgia, Forente stater, 30303
        • Rekruttering
        • Grady Health
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Nicole A Zelenski, MD
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • University of Chicago
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jeffrey Stepan, MD
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40202
        • Rekruttering
        • University of Louisville
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Tuna Ozyurekoglu, MD
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70112
        • Rekruttering
        • Louisiana State University Health Sciences Center
        • Hovedetterforsker:
          • Harvey Chim, MD, FACS
        • Ta kontakt med:
        • Ta kontakt med:
          • Tanja Milosavljevic, MSc, PhD
          • Telefonnummer: 504-568-6876
          • E-post: tmilos@lsuhsc.edu
    • Maryland
      • Baltimore, Maryland, Forente stater, 21218
        • Rekruttering
        • Curtis National Center at MedStar Union Memorial Hospital
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kenneth R Means Jr., MD
    • Missouri
      • Columbia, Missouri, Forente stater, 65211
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Barnes-Jewish Hospital 1 Barnes Jewish Hospital Plaza St.
        • Ta kontakt med:
        • Hovedetterforsker:
          • David M Brogan, MD, MSc
        • Ta kontakt med:
    • New Jersey
      • Camden, New Jersey, Forente stater, 08103
        • Rekruttering
        • The Cooper Health System
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • David A Fuller, MD
    • New York
      • New York, New York, Forente stater, 10003
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45267
        • Rekruttering
        • UC Health
        • Hovedetterforsker:
          • Sonu Jain, MD
        • Ta kontakt med:
        • Ta kontakt med:
          • Brittany Rowley, CCRC Clinical Research Professional III
          • Telefonnummer: 513-558-2765
          • E-post: rowleybm@ucmail.uc.edu
      • Cincinnati, Ohio, Forente stater, 45267
        • Rekruttering
        • University of Cincinnati Health
        • Hovedetterforsker:
          • Sonu Jain, MD
        • Ta kontakt med:
        • Ta kontakt med:
      • Cleveland, Ohio, Forente stater, 44109
        • Rekruttering
        • The MetroHealth System
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kyle Chepla, MD
      • Columbus, Ohio, Forente stater, 43212
        • Rekruttering
        • The Ohio State University Wexner Medical Center
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ryan Schmucker, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • University of Pennsylvania, Department of Orthopaedic Surgery
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ines C Lin, MD
      • Pittsburgh, Pennsylvania, Forente stater, 15212
        • Rekruttering
        • Allegheny Health Network
        • Ta kontakt med:
        • Ta kontakt med:
          • Mary Fetter - Lead Clinical Research Coordinator
          • Telefonnummer: 412-359-8292
          • E-post: Mary.Fetter@ahn.org
        • Hovedetterforsker:
          • Steven Regal, MD
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29429
        • Rekruttering
        • Medical University of South Carolina
        • Ta kontakt med:
        • Ta kontakt med:
          • Charles A Daly, MD
          • Telefonnummer: 843-876-2211
          • E-post: dalyc@musc.edu
        • Hovedetterforsker:
          • Charles Daly, MD
    • Texas
      • Dallas, Texas, Forente stater, 75246
        • Rekruttering
        • Baylor, Scott and White Health
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Asadullah Helal, MD
      • Lubbock, Texas, Forente stater, 79415
        • Rekruttering
        • Texas Tech
        • Hovedetterforsker:
          • Brendan MacKay, MD
        • Ta kontakt med:
        • Ta kontakt med:
    • Utah
      • Salt Lake City, Utah, Forente stater, 84132
        • Rekruttering
        • University of Utah Health
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mark Mahan, MD, FAANS
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22903
        • Rekruttering
        • UVA Health
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Brett DeGeorge, MD
    • Washington
      • Seattle, Washington, Forente stater, 98104
        • Rekruttering
        • Harborview Medical Center
        • Ta kontakt med:
        • Ta kontakt med:
          • Yusha ( Katie) Liu, MD PhD
          • Telefonnummer: 206-744-3000
          • E-post: HMCnerve@uw.edu
        • Hovedetterforsker:
          • Katie Liu, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • The subject has voluntarily agreed to participate in this study and has signed an Institutional Review Board (IRB) approved informed consent form.
  • The subject is between eighteen (18) and eighty (80) years of age.
  • The subject has clinical evidence of a Sunderland's 4th degree (Class II) or 5th degree (Class III) nerve transection(s) that has resulted in upper extremity nerve impairment that requires surgical treatment.

Exclusion Criteria:

  • Subjects whose nerve repair will occur greater than 48 hours after nerve transection.
  • Subjects requiring nerve repair involving an autograft, allograft or conduit(s).
  • Subjects with multiple transected nerve injuries are allowed into the study only if all injuries are amenable to direct repair.
  • Subjects who, in the judgement of the investigator, are not likely to demonstrate meaningful recovery within a reasonable time frame during follow up due to significant muscle atrophy or other morbidity.
  • The subject's injury is a result of a suicide attempt or self- harm.
  • The subject has documented history or clinical signs of any condition where NTX-001 might not prove beneficial (e.g., systemic neuromuscular disease, systemic neurological deficit, or other treatments known to affect the growth and/or physiology of the neural and vascular system).
  • The subject has a known allergy to polyethylene glycol (PEG) or human grade silicone.
  • The subject is pregnant or breastfeeding.
  • The subject is currently enrolled in another investigational study or has participated in an investigational study within 30 days prior to screening.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: NTX-001

NTX-001 used during the surgical repair of an upper extremity peripheral nerve injury in conjunction with standard suture neurorrhaphy.

One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.

Ingen inngripen: Standard Suture Neurorrhaphy

Standard of Care

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mean Michigan Hand Questionnaire (MHQ) Two Domain Score (ADL and Pain)
Tidsramme: Screening Visit, Week 24

The subject will complete the MHQ questionnaire at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48. A measure of the mean of MHQ in the Two Domains, Activities of Daily Living and Pain Scores, at Week 24 in the NTX-001 group as compared to Standard of Care (SoC). In the ADL subdomain, a higher component score indicates better function. In the Pain subdomain, a higher component score indicates greater pain. A total MHQ score of 100 is considered the best functional score.

Screening Visit, Week 24
Safety - Columbia-Suicide Severity Rating Scale
Tidsramme: Screening Visit, Weeks 4, 12, and 48

The Columbia-Suicide Severity Rating Scale (C-SSRS) is a suicide risk assessment tool. The C-SSRS tool asks; whether and when the subject has had a thought about suicide (ideation); what actions they might have taken and what they did to prepare for suicide; whether and when they attempted suicide or began a suicide attempt that was either interrupted by another person or stopped of their own volition. The answers identify whether someone is at risk for suicide, assessing the severity and immediacy of that risk, and gauging the level of support that the person needs. The first assessment is done by study staff at screening. Subsequent assessments will be completed by the subject at Weeks 4, 12, and 48. A score of 0 indicates no risk, 1-2 indicates low risk, and 3+ indicates moderate to high risk.

Screening Visit, Weeks 4, 12, and 48

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Intraoperative CheckPoint® Stimulation.
Tidsramme: In Operating Room

A CheckPoint® Stimulator will be used intra-operatively to detect immediate reconnection of severed peripheral nerves (axons) in mixed-motor nerves only. The measures include in response of direct nerve stimulation, proximally and distally to suture site.

In Operating Room
MHQ Total Score
Tidsramme: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48

The MHQ quantifies different impairments between the subjects in uninjured and involved upper extremities. A general survey of hand function includes twenty-five items for the right and the left hand, as well as questions for both hands. Questions regarding function specifically refer to the impact of the involved hand and/or wrist on the activity which presumably takes all joints of the upper extremity into account. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.

Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48
Time to Return to Function
Tidsramme: Screening Visit, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.

Achievement of seventy-five (75)% function in the combined ADL and pain MHQ domain scores. The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.

Screening Visit, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Change in NPRS
Tidsramme: Screening Visit, Weeks 2, 4, 6, 8, 10, 12,16, 20, 24, 30, 36, 42, and 48

The NPRS is used to assess for pain and to determine pain intensity. The NPRS is an 11-point scale scored from 0-10: 1) "0" = no pain 2) "10" = the most intense pain imaginable. The average of the 3 ratings is used to represent the subject's level of pain over the previous 24 hours.

Screening Visit, Weeks 2, 4, 6, 8, 10, 12,16, 20, 24, 30, 36, 42, and 48
Semmes Weinstein Monofilament Test (SWMT)
Tidsramme: Weeks 2, 4, 8, 12, 24, 36, 48.

SWMT provides information on protective sensation, the rigorous system can detect relatively minor differences in sensory function, and changes will occur early in nerve injury. The assessment tool consists of a set of monofilaments that vary in thickness and diameter, the gradient forces of these monofilaments that subjects' can feel, range from 0.086 gm to 0.448gm. The normal value in the hand is in the range of the green filament (1.65 to 2.83 mN).

Weeks 2, 4, 8, 12, 24, 36, 48.
MHQ Two Domain Score
Tidsramme: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, 48

The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The raw scale score for each of the 6 scales is the sum of the responses of each scale item. The raw score is converted to a score range from 0 to 100. 100 being the best.

Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, 48
Change from Week 2 in MHQ Two Domain Score
Tidsramme: Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.

The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The raw scale score for each of the 6 scales is the sum of the responses of each scale item. The raw score is converted to a score range from 0 to 100. 100 being the best.

Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Medical Research Council Classification (MRCC) Sensory Score
Tidsramme: Weeks 2, 4, 8, 12, 24, 36, and 48.

The scale is commonly used including 2 Point Discrimination for grading the sensory outcome after peripheral nerve surgery. This scale is categorized into S0-S4: S0 is the absence of sensibility; S1 is the recovery of deep cutaneous pain; S2 is the return of superficial cutaneous pain and some degree of tactile sensibility; S3 is the return of superficial cutaneous pain and tactile sensibility without over response; and S4 is the complete recovery.

Weeks 2, 4, 8, 12, 24, 36, and 48.
Medical Research Council Classification (MRCC) Motor Score
Tidsramme: Weeks 2, 4, 8, 12, 24, 36, 48

This assessment is conducted on mixed motor nerve injuries only. Strength can best be assessed by isolating an individual muscle group and comparing power with that of the subject. It can be conducted to assess larger muscles or muscle groups as well as intrinsic muscles of the hand. Measuring the difference between the affected limb and the contralateral limb. 0/5 is no muscle activation whatsoever; 1/5 is muscle activation without limb movement; 2/5 implies that the limb can be moved only when gravity is taken out of the equation; 3/5 means that the subject can overcome gravity but not resistance;• 4/5 (or 4+ or 4-) implies weakness with enough strength to overcome varying degrees of physical resistance; 5/5 is full strength.

Weeks 2, 4, 8, 12, 24, 36, 48
Change from Baseline (W2) in Numeric Pain Rating Scale (NPRS)
Tidsramme: Weeks 2, 24.

The NPRS is used to assess for pain and to determine pain intensity. The NPRS is an 11-point scale scored from 0-10: 1) "0" = no pain 2) "10" = the most intense pain imaginable. The average of the 3 ratings is used to represent the subject's level of pain over the previous 24 hours.

Weeks 2, 24.
Patient Global Impression of Change Score
Tidsramme: Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, and 48

This scale evaluates all aspects of patients; health and assesses if there has been an improvement or decline in clinical status. PGIC is a 7-point scale depicting a subjects rating of overall improvement. The subject rates their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."

Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, and 48
Change in Total MHQ Score
Tidsramme: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.

The MHQ quantifies different impairments between the subjects uninjured and involved upper extremities. It was designed as a general survey of hand function and includes twenty-five items for the right and the left hand, as well as questions for both hands. Furthermore, questions regarding function specifically refer to the impact of the involved hand and/or wrist on the activity which presumably takes all joints of the upper extremity into account. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.

Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Change from Baseline in Patient Global Impression of Severity Score (PGIS)
Tidsramme: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42 and 48.

The PGIS is a single question asking the subject to rate the severity of the injury from the last visit. PGIS is a scale depicting a subject's rating of overall severity. The subject scores their perception of severity as "none," "mild," "moderate," "severe," or "very severe."

Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42 and 48.

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Electromyography (EMG) Testing
Tidsramme: Weeks 12, 24.

EMG will be used to detect reconnection of severed peripheral nerves (axons) using PEG Fusion. Restoration of nerve conduction indicates the restoration of axon continuity, which is a prerequisite for the prevention of Wallerian degeneration, neuromuscular junction degeneration, muscle atrophy and functional recovery. This testing will be done at select clinical sites.

Weeks 12, 24.
Nerve Conduction Velocity (NCV)
Tidsramme: Weeks 12, 24

NVC testing measures how fast an electrical impulse moves through a nerve. This testing will be done at select clinical sites.

Weeks 12, 24
Physical and Occupational Therapy
Tidsramme: Weeks 2, 4, 8, 12, 24, 36, and 48.

Each subject will have the number of times physical therapy and/or occupational therapy is prescribed to determine if this activity affects the sensory and functional outcomes of the nerve repair between NTX-001 and SOC.

Weeks 2, 4, 8, 12, 24, 36, and 48.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Seth Schulman, MD, Neuraptive Therapeutics Inc.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. februar 2025

Primær fullføring (Antatt)

31. mars 2027

Studiet fullført (Antatt)

30. april 2027

Datoer for studieregistrering

Først innsendt

24. september 2024

Først innsendt som oppfylte QC-kriteriene

24. september 2024

Først lagt ut (Faktiske)

27. september 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. oktober 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere